Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

Linda-Gail Bekker <a class=“affiliation-link” title=“From the Desmond Tutu HIV Centre (L.-G.B., K.G., G.N., Y.S.) and the Department of Medicine, Vuka Research Clinic (A.M.W.), University of Cape Town, Cape Town, the Department of Epidemiology and Prevention, …